[History--hunting for old books].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to E Petersen.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A gene coding for a 220-kDa glutamate rich protein (GLURP), an exoantigen of Plasmodium falciparum, was isolated and its nucleotide sequence was determined. The deduced amino acid sequence contains 2 repeat regions. The sequence of one of these was shown to be conserved among geographically dispersed isolates, and a fusion protein containing that sequence was able to stimulate B- and T-cells. Antibodies against GLURP stained erythrocytic stages of the parasite as well as the hepatic stage as detected by electron microscopy.
Occurrence of fevers and chills, headaches and body and joint pains, and body temperature and malaria parasitaemias were recorded monthly for a year for 121 Liberian adults. There was no apparent correlation between any of the symptoms and the presence or density of blood parasites; it was therefore not possible to define a case of clinical malaria in the study population, which was probably highly immune to infection. Only a few people with patent blood infections had elevated blood temperatures and these were below 37.5 degrees C. Malaria prevalence and levels of parasitaemia declined with age and indicated that immunity continues to develop well into adult age. The data did not support the view that adults experience symptoms at lower parasitaemias than children. Pregnant and non-pregnant women had similar levels of symptoms, but high levels of parasitaemia were found more frequently in the pregnant group.
A total of 1622 individuals of all ages living under conditions of continuous malarial transmission in Liberia were enrolled in a cross-sectional study of parasite rates, positive parasite densities, and body temperatures. The age-specific Plasmodium falciparum-positive parasite densities were greatest at ages 0.5-1.0 year, then slowly declined into adulthood. The age-specific mean body temperature at parasite isodensity showed a steady decline even in the oldest age group. The results do not support the hypothesis that adults have higher body temperatures at a given parasite density than do children with the same parasite density. The age-specific P. falciparum parasite density for specific isotemperatures showed that a subgroup of children in the age group 0.5-1.0 year had low temperatures (less than 36.5 degrees C) despite high parasite densities. This indicates that low body temperature should be investigated further as a possible indicator of serious malaria in young children. Parasitologic and clinical immunity develops concomitantly and cannot be separated. The findings do not support the hypothesis that a special "anti-disease" immunity exists independently of parasitologic immunity.
The seroreactivities to Pf155/RESA antigen and to three oligopeptides (EENV)2, EENVEHDA and K(DDEHVEEPTVA)2, which constitute repeat subunits of the RESA molecule, were investigated between 1980 and 1986 in two cohorts of children (n = 114) with and without monthly chemosuppression (pulsed reduction of parasite load) against malaria from six months to five years of age during development of protective immunity. Serum samples were collected first at half-yearly and then yearly intervals. Positive immunofluorescence against Pf155/RESA (EMIF) was only found in 24% of the samples. The children with chemosuppression were more often seropositive (30%) than the non prophylactic children (17%). This was in contrast to the seroreactivity against crude parasitic antigens which was highest in the non prophylactic children. In these children, there was a general decrease of EMIF titres around two years of age. Immunosuppression by chronic parasitaemia may be suggested as a reason for this. ELISA seroreactivity was found against one, two or three oligopeptides in all children with high EMIF titres (greater than 250) although (EENV)2 appeared to best correlate (92%) with the EMIF seropositivity. While EMIF seropositivity only showed partial correlation to immunoprotection against patent parasitaemia in the non prophylactic children, the individual profiles of the seroreactivities to the different specific epitopes of the Pf155/RESA molecule and their relevance with regards to protective immunity to malaria need to be investigated further.
In order to assess the protective effects of anti-Pf155/RESA antibodies of different specificities in vivo, passive immunizations of Aotus monkeys were performed. Antibodies reactive with the Pf155/RESA repeat sequences (EENV)2 and EENVEHDA were isolated from the immunoglobulin G (IgG) fraction of a pool of plasmas from Liberia by affinity chromatography on synthetic peptides. The two fractions of antibodies differed in specificity but displayed similar capacities to inhibit merozoite invasion in Plasmodium falciparum in vitro cultures. Four groups of monkeys (named groups I to IV) were injected with (i) 160 mg of total control IgG, (ii) 2 mg of IgG affinity purified on (EENV)2, (iii) 2 mg of IgG affinity purified on EENVEHDA, and (iv) 160 mg of total immune IgG, respectively. The monkeys were then challenged with P. falciparum-infected erythrocytes, and the levels of parasitemia and hematocrits as well as other serological parameters were determined daily. Although all groups developed parasitemia, groups II and IV tended to show lower mean daily levels. Three monkeys of group II and two monkeys (each) of groups III and IV self cured the infections, but so did one monkey from the group treated with control IgG (group I). The serum levels of transfused antibodies were low at the peak of parasitemia, suggesting that clearance of parasites was mediated by immune responses mounted by the monkeys. The results indicate that antibodies to epitopes formed by repeats of Pf155/RESA may depress P. falciparum parasitemias and thus that immunogens based on such repeats should be suitable components in a subunit vaccine against asexual stages of P. falciparum.
Investigators studied 348 children age 0-10 years, living in a holoendemic area of Liberia, for parasitological, serological and clinical parameters. The age-specific parasite rate increased towards the 7-10 year-old age group in which it was 86.8%. The geometrical mean parasite density decreased from the 3-4 year-old age group, in which fewer episodes of clinical malaria were observed. Antibodies to crude Plasmodium falciparum parasite antigens were detected in all children. The (EENV)6 seropositive rate was a maximum of 67.9% in the 3-11 month-old age group. It declined to a minimum of 31.7% in the 5-6 years age group after which it increased slowly in the 7-10 years age group. Antibodies to the synthetic peptide (NANP)6 showed a steady seropositive rate after the age of 3 months, between 30.0% and 39.3% in all the age groups up to 10 years. No statistically significant correlation was found between seropositivity to (EENV)6 and malarial parasitemia. In contrast, a statistically significant positive correlation was found between seropositivity to (NANP)6 and parasite rates. The antibody response for the individual child was transient to both Pf155/RESA, measured by immunofluorescence, and to (EENV)6 and (NANP)6, measured by ELISA, especially in the younger age groups of this study population. Parasitological and clinical immunity developed before a stable antibody response to these defined malaria antigens was established. These antibodies may still contribute to the immune protection against malaria, but they were not reliable parameters for protective immunity in the population we studied.
A method for purification of a recombinant Plasmodium falciparum protein produced in E. coli and its use in an enzyme-linked immunosorbent assay (ELISA) is described. The cloned gene fragment encodes GLURP,489-1271 the carboxy-terminal 783 amino acid residue portion of a 1271 amino acid residue P. falciparum glutamate rich protein (GLURP), with a molecular weight of 220 kilodalton. The protein is associated with all parasite stages in the human host. Examination of sera from 105 adult Liberians living in a malaria endemic area revealed anti-GLURP IgG antibodies in 98% of the sera. The recombinant GLURP489-1271 was expressed as a chimeric protein, fused with E. coli beta-galactosidase. However, antibodies in sera were directed only against the malaria part of the fusion protein and not against beta-galactosidase. Antigen from in vitro P. falciparum cultures of isolates from Tanzania (F32), Papua New Guinea (MAD20) and Honduras (HB3) completely absorbed specific antibodies, indicating the presence of conserved epitopes produced by all isolates of P. falciparum. Recombinant GLURP489-1271 ELISA is sensitive and rapid, and therefore well-suited for sero-epidemiological studies, and for control of the immunogenicity of a possible future P. falciparum vaccine utilizing epitopes from GLURP.
Failures in the prophylactic effect of the antimalarial biguanide chlorproguanil (Lapudrine) may be caused by insufficient levels of its active metabolite chlorcycloguanil. Concentrations of chlorproguanil, chlorcycloguanil and a second metabolite, dichlorophenylbiguanide, in plasma, erythrocytes and urine, were followed in 13 volunteers, using a HPLC assay. In an initial study the basic kinetics were investigated after an oral dose of 2 mg kg-1. In the main study, the concentration-time curves were followed for 1 week after an oral dose of 20 or 80 mg chlorproguanil, respectively, after either a single dose or one weekly dose for 5 weeks. Higher concentrations of all three compounds were found in erythrocytes than in plasma. The active substance, chlorcycloguanil, was below the probably effective concentration in erythrocytes 24 h after 20 mg chlorproguanil and 72 h after 80 mg. The urinary recovery was about 45% of the dose and t1/2 31-44 h, both higher than previously reported. The apparent clearance was 0.52-0.82 l h-1 kg-1, which is lower than previously found. It is suggested that improved dose regimens, e.g. a higher dose given once a week, should be clinically tested on basis of these kinetic results.
Explore the source record for details and available documents.
Traditional malaria control is in a crisis on account of chemo-resistance of Plasmodium falciparum and insecticide-resistance of the malaria mosquito. New ways to control malaria have been opened by the possibility of producing a vaccine. Several malaria proteins (e.g. CSP, gp195, Pf155/RESA, GLURP) have been sequenced and it has been shown that most of the proteins have repetitive units. Analyses of T- and B-cell epitopes show that T-cell epitopes are mainly localized to the non-conserved parts of the antigens. Repeated malaria infections, therefore, may be seen as a number of primary infections, which partly explains the very slow development of immunity to the parasite. The initial three vaccination experiments in humans did not succeed in inducing a complete protection of the individual but it showed that partial immunization is possible.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In vivo susceptibility of Plasmodium falciparum to chlorproguanil and in vitro susceptibility to pyrimethamine, cycloguanil and chlorcycloguanil were studied in 38 children from two Liberian villages. Children in one village (Lagbala) had received monthly chemosuppression with chlorproguanil from 1976-1985, and children in the other village (JDF) had received fortnightly chlorproguanil from 1981-1985. The highest and lowest IC100 for pyrimethamine differed by a factor of 10(5), but they differed only by a factor of 10(3) for chlorcycloguanil. The mean IC100 for chlorcycloguanil was significantly lower (P less than 0.0001) than the mean IC100 for pyrimethamine and cycloguanil, and the IC100 for the samples most resistant to chlorcycloguanil (10(-8) M) was still well below peak blood concentrations after chlorproguanil administration. Resistance could be defined as IC100 greater than or equal to 10(-6) M for pyrimethamine and IC100 greater than or equal to 10(-8) M for chlorcycloguanil. The isolates most resistant or most sensitive to pyrimethamine were also the most resistant or most sensitive to chlorcycloguanil, indicating partial cross-resistance between the two drugs. The in vivo response to chlorproguanil 1.5 mg kg-1 in Lagbala was equal to the response in 1983. Chlorproguanil 1.5 mg kg-1 resulted in lower parasite rates on day 3 and 7, but did not prevent 60% of the children requiring treatment with chloroquine during the four weeks' follow-up after chlorproguanil administration.